47 results
424B5
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Prospectus supplement for primary offering
4:04pm
on many factors, including our research, development, sales and marketing activities. We may need to raise additional capital through public or private … expectations and/or predictions of success of our current and future research and development programs and preclinical studies, including our expectations
424B5
GLUE
Monte Rosa Therapeutics Inc
15 May 24
Prospectus supplement for primary offering
4:04pm
stock.
Our future capital requirements depend on many factors, including our research, development, sales and marketing activities. We may need … , timing, progress, results, costs, and any expectations and/or predictions of success of our current and future research and development programs
8-K
EX-99.1
GLUE
Monte Rosa Therapeutics Inc
9 May 24
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
7:05am
revenue recorded under the Roche License and Collaboration agreement.
Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2024 … )
(unaudited)
Three months ended
March 31,
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating
8-K
EX-99.1
gqodoja3
14 Mar 24
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:05am
8-K
EX-99.1
e6hn4l 6l9o47a29
9 Nov 23
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
7:27am
424B5
hyfo0jw96wg39 bb10
26 Oct 23
Prospectus supplement for primary offering
4:55pm
8-K
EX-99.1
b1jz4jol
10 Aug 23
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
7:19am
8-K
EX-99.1
f1mc algn
11 May 23
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
7:34am
PRE 14A
fi7mp5zr
12 Apr 23
Preliminary proxy
4:07pm
8-K
EX-99.1
s8ea0 0i5adyyatji
10 Nov 22
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
7:36am
8-K
EX-99.1
0626jy
11 Aug 22
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
7:35am